https://www.cumberlandpharma.com/second-quarter-2024-updates-including-double-digit-revenue-growth/2024-08-14T12:24:08-05:00https://www.cumberlandpharma.com/first-quarter-2024-updates-including-a-special-report-for-our-caldolor-product/2024-05-15T10:49:00-05:00https://www.cumberlandpharma.com/2023-highlights-including-expanded-fda-approval-and-new-study-publications/2024-03-13T09:55:25-05:00https://www.cumberlandpharma.com/third-quarter-2023-updates-including-our-new-mission-statement/2023-11-14T08:45:52-06:00https://www.cumberlandpharma.com/second-quarter-2023-updates-including-expanded-fda-approval-for-caldolor-and-publication-of-newborn-clinical-study-results/2023-08-14T08:53:41-05:00https://www.cumberlandpharma.com/first-quarter-2023-updates-including-nopain-act-and-fda-fee-waiver/2023-05-16T09:27:19-05:00https://www.cumberlandpharma.com/early-2025-milestones/2025-03-12T11:06:42-05:00https://www.cumberlandpharma.com/november-2024-updates-highlighting-key-clinical-and-business-developments/2024-11-01T11:11:51-05:00https://www.cumberlandpharma.com/first-quarter-2025-updates-including-breakthrough-phase-2-dmd-study-results/2025-05-14T01:00:27-05:00https://www.cumberlandpharma.com/second-quarter-2025-updates-include-new-clinical-data-financial-momentum/2025-08-13T13:28:12-05:00https://www.cumberlandpharma.com/third-quarter-2025-updates-including-new-product-addition-and-international-expansion/2025-11-12T07:40:12-06:00https://www.cumberlandpharma.com/2025-year-end-update-strong-financial-performance-new-portfioio-addition-global-expansion-and-pipeline-progress/2026-03-13T09:57:02-05:00https://www.cumberlandpharma.com/first-quarter-2026-update/2026-05-14T09:27:08-05:00https://www.cumberlandpharma.com/second-quarter-2026-updates/2026-08-12T13:41:38-05:00